Maprelin, which contains a new active molecule, Peforelin, is a gonadotropin releasing hormone (GnRH). A single, low volume injection of the ready-to-use solution induces oestrus in sows after weaning, and in sexually mature gilts where oestrus has been synchronised with Regumate Porcine.
According to the company, it works by selectively inducing the release of the animal's own follicle stimulating hormone (FSH), leading to follicle growth - critical to successful reproduction - and the stimulation of oestrus. Conventional GnRHs, because of their mode of action, are used mainly to induce ovulation.
Janssen says Maprelin is the next step in its pig reproduction programme, named Syncoris. Cornerstone of this programme is Regumate for gilt synchronisation.
Trials have shown that with the use of Maprelin (compared with control groups of breeding animals) the number of gilts and sows showing oestrus within six days of treatment increased by about 15 percentage points (Table 1). For first-litter sows the figure was more than 8 percentage points. The duration of oestrus was not affected.
Gilts came on heat two days faster than with Regumate alone, and the weaning to oestrus interval with sows achieved similar statistically significant reductions.
Farrowing rate increased by over 5 per cent for sows, by 6 per cent for first-litter sows and just on 8 per cent for gilts.
Added to those benefits, for each 100 inseminations sows produced an extra 104 piglets, first-litter sows 105 and gilts an even more impressive 158. All gilt groups in the trials, including the control groups, were synchronised with Regumate. With unsynchronised gilts it is not possible to predict the correct time to inject Maprelin.
Phil Macdonald, the company's UK pig and poultry business manager, says the objective of every producer is profitable pigmeat production. "In the UK and other EU states the costs of feed, housing and labour are considerably higher than in other major pig-producing sectors of the world.
"This makes it important for UK producers to optimise management of the reproductive process. Maprelin is a valuable tool that can help with this objective."
The precision injection gun with Maprelin enables accurate delivery of the small amounts required. Gilts require a 2.0 ml dose 48 hours after their last Regumate treatment, first-litter sows a 0.5 ml dose 24 hours after weaning and multi-litter sows 2.0 ml 24 hours after weaning. Injections are intramuscular.
The solution requires no mixing, reducing the possibility for errors. Opened vials have a shelf life of 28 days and unopened vials a shelf life of two years. Sows and gilts need only one injection per parity, and the withdrawal period for meat and offal is zero days.
Intervet/Schering-Plough Animal Health, makers of Caninsulin, is launching Pet Diabetes Month, a call to arms for owners to check if their pets might be at risk of diabetes. To enable the testing, urine glucose test strips will be made available free of charge to vet practices to dispense during Pet Diabetes Month (1 - 30 November 2009).
ISPAH says that despite general awareness of the signs of diabetes in humans, many pet owners still have little understanding of the condition in their animals. The urine-sampling aspect of the campaign, entitled the Great Pet 'Pee' Test, intends to address this by making test strips freely available. It is hoped that many of the undiagnosed diabetics in the UK's pet population will be identified during the campaign and appropriate treatment plans undertaken.
Practices wishing to participate in Pet Diabetes Month and the Great Pet 'Pee' Test will benefit from practice leaflets containing the test strips, waiting room posters, the website http://www.petdiabetesmonth.co.uk/ and the opportunity to be included in a regional PR campaign.
Shoumik Das BVM&S MRCVS, Marketing Manager for Caninsulin, said; "The tremendous success of National Vaccination Month clearly demonstrates that pet owners are keen to take an active interest in the care of their pet, but often don't know where to start. By providing the test strips free to practices to distribute to pet owners we are once again giving them the tools to take control of their pets' health. If we can identify even a few of the missing thousands of pets potentially at risk from diabetes, that has to be good news for the pets and also vet practices."
Interested practices should contact their local Intervet/Schering-Plough Territory Manager or phone the company's Veterinary Support Group on 01908 685685.
VetCell Bioscience has become the first UK-based stem cell centre to be authorised under the Veterinary Medicines Regulations.
Following a rigorous series of inspections and reports by Good Manufacturing Practice (GMP) Inspectors VetCell, in conjunction with their UK laboratory partner Biobest, were officially authorised as an equine stem cell centre on 1 October 2009.
David Mountford, Chief Operating Officer of VetCell Bioscience said: "To have received formal authorisation so swiftly reflects the high standard of our operation and our ability to lead the field in the increasingly competitive sector of stem cell technology."
Stem cell therapy involves implanting millions of the animal's own stem cells and autologous growth factors directly into the injured tendon or ligament. The service VetCell Bioscience offers is the collection, storage, processing and supply of stem cells suitable for administration back into the donor animal.
According to the company, there is considerable interest from the human sector and studies in human medicine, for the treatment of Achilles tendinopathies, could begin as early as next year.
Novartis Animal Health has announced that it will no longer be manufacturing and supplying the enzootic abortion vaccine, Mydiavac.
The company reassures its customers that current stocks will continue to be distributed as smoothly as possible.
A mutation responsible for Primary Lens Luxation (PLL), a painful and blinding inherited eye condition, has been indentified by geneticists working in the Kennel Club Genetics Centre at the Animal Health Trust. They expect a DNA test to identify carriers of the mutation to be available by late October, 2009.
The team led by Dr Cathryn Mellersh, in collaboration with Dr David Sargan (Cambridge University) and Dr David Gould (Davies Veterinary Specialists), believe the discovery could prevent the development of PLL in several breeds of terriers.
Miniature Bull Terriers, Lancashire Heelers, Tibetan Terriers, Jack Russell Terriers, Parson Russell Terriers, Patterdale Terriers, Sealyham Terriers and Chinese Crested dogs will all benefit from the findings.
Dr Cathryn Mellersh, said: "This is an exciting discovery for many breeds of dogs across the world. We have identified the mutation, and soon we'll be able to give advice on breeding strategies. Hopefully in time we'll eradicate this awful condition from many breeds of dogs."
In the near future a simple test kit will be available for breeders and owners to test their dogs. It will be possible to collect DNA from a simple cheek swab.
The DNA test will enable breeders to ascertain the likelihood of each dog's risk of developing PLL. Breeders will then be able to make informed decisions about which dogs to breed. This will minimise the risk of producing dogs that will become affected by the serious and debilitating condition.
In affected dogs PLL causes fibres which support the lens to breakdown or disintegrate, causing the lens to fall into the wrong place in the eye. Depending on where the lens falls, it can cause glaucoma or loss of vision.
Caroline Kisko, Communication Director at the Kennel Club, commented: "This is truly a major breakthrough at the Kennel Club Genetics Centre in our fight to eliminate many of the inherited diseases dogs have, all made possible with funding from the Kennel Club Charitable Trust.
"PLL is a painful and blinding condition, and we hope once the DNA test is available at the end of next month we will be able to eliminate this condition altogether."
Dr. Mellersh, added: "We would like to sincerely thank all the owners and breeders who have contributed DNA and information from their dogs to this project. The discovery would not have been possible without them."
Vetoquinol has announced that packs of Rubenal 300mg are now available in bottles of 60 tablets instead of the previous 20.
Rubenal, which was launched earlier this year, is a complementary nutritional feeding stuff for the support of renal function in case of chronic renal insufficiency in dogs and cats. It is used as an aid to the maintenance of the normal renal fibrous architecture.
Simon Boulton, Rubenal's product manager said: "This increased pack size is a direct result of customer consultation. It will make treatment more cost effective for dogs and allow a longer treatment period per pack purchased."
For further information please contact your Vetoquinol representative or telephone 0800 1698197.
Dechra Veterinary Products, manufacturer and distributor of Equipalazone®, has launched a new website with up-to-date advice and guidance on the subject of equine pain management for horse owners: http://www.equinepainmatters.com/
Dechra says the website offers owners a place to go for information about pain in their horse including causes, diagnosis and the tools and techniques that their vet may use to treat pain. Owners will also be able to download anatomy charts and information leaflets on topics such as pain management, lameness, anaesthesia, sedation, euthanasia, the importance of microchipping and wound management.
Larry King, equine product manager at Dechra said: "This website is great for horse owners as they now have one place to go for information about equine pain matters. It will help them gain a better understanding of managing pain in their horses and the critical role that their vet plays in this area. Veterinary practices can also refer owners to it to support their consultation. This is the first website to put all this information together, so we are sure it will be popular.
"Cards with the new website address are available for practices to hand out to clients. "The website allows clients to browse the site in the comfort of their own home and is also ideal for practices with limited storage space for client information materials."
Dechra also encourages practices that have their own websites to link directly to www.equinepainmatters.com. Practices can order hand-out cards by contacting Dechra on 01743 441632 or email marketing@dechra.com.
Following a two-year postponed judgment, the Disciplinary Committee (DC) of the Royal College of Veterinary Surgeons last week warned a Cambridgeshire veterinary surgeon as to his future conduct, after he had been convicted in 2006 for causing death by careless driving whilst under the influence of alcohol.
In September 2007, the Committee heard that Peter Hanlon MRCVS, of Soham in Cambridgeshire, had been involved in a road traffic accident in February 2006. Mr Hanlon's car had drifted across the road and collided with an oncoming car driven by James Barber who was accompanied by his wife, Ivy. Mr Barber was pronounced dead at the scene and both Mrs Barber and Mr Hanlon sustained injuries.
At the initial hearing, Mr Hanlon admitted the conviction (for which he had been sentenced to 30 months in prison and received a four-year driving ban) and the charge that it rendered him unfit to practise veterinary surgery. The Committee decided to postpone its judgment for two years on the agreement that Mr Hanlon would undertake to abstain from alcohol and to submit quarterly medical reports and six-monthly CPD (continuing professional development) reports to the Committee chairman.
At the resumed hearing last week, the Committee carefully considered Mr Hanlon's written and oral submissions, and accepted that he had fully complied with these undertakings. He had abstained from alcohol since the day after the accident, produced an "exemplary" CPD record and provided impressive reports from his employers concerning his professional competence.
In addition, Mr Hanlon, who spent around 14 months in prison and remained on licence until July 2009, also reiterated to the Committee his remorse for the death of Mr Barber and respect for his family.
The Committee was mindful of its duty to maintain confidence in the veterinary profession and uphold proper standards of conduct. Whilst it did not consider it necessary to postpone judgment again, it felt that Mr Hanlon should be warned about his future conduct.
Caroline Freedman, chairing the Committee, concluded: "As this case has demonstrated, and as Mr Hanlon himself has fully recognised, abuse of alcohol can lead to far reaching consequences in personal and professional lives and the lives of others."
Vets Now, the out-of-hours emergency services provider is to launch the Vets Now Hospital service in Glasgow city centre, where it will offer emergency and critical care together with a range of specialist referral options.
This follows on the heels of The University of Glasgow Small Animal Hospital, a new £15 million facility which opened at the end of August.
Vets Now says that the new hospitals and the range of clinical services on offer to the profession and pet owners will make the west of Scotland a centre of excellence in advanced clinical care for animals.
The opening of the two facilities will also offer both organisations a new platform on which to develop further their long standing relationship through future collaboration in the areas of teaching, training and investigation into animal disease.
Vets Now Group Managing Director, Richard Dixon said: "The opening of the two facilities presents a number of opportunities for both organisations to work collaboratively to develop teaching and training for undergraduates, residents, interns and nurses, and to work together to gain further understanding into animal disease through clinical investigation and the practice and promotion of evidence based medicine."
Professor Stuart Reid, Dean of the Faculty of Veterinary Medicine at the University said: "The expanded service which will be offered by the Small Animal Hospital and the new Vets Now Hospital obviously presents an enhanced range of choices for pet owners and first opinion vets in Scotland and an opportunity for both organisations to work collaboratively to ensure that undergraduates and clinical professionals have access to the best training and opportunities to develop professionally. We have enjoyed a mutually beneficial relationship for a number of years and we look forward to the new opportunities which the opening of the two hospitals will bring in the future."
The Small Animal Hospital opened on 31 August. The first Vets Now Hospital will open in Glasgow on 31 October.
Boehringer Ingelheim Vetmedica has launched a unique and natural muscle building supplement for horses, Equitop Myoplast Power Pearls, containing 18 key amino acids.
The company says maintaining muscular condition in performance and sports horses can be challenging, especially when work load is increased or during periods of convalescence, as feeding high levels of concentrates can often lead to horses becoming 'fizzy' and bulking up on fats and oils.
Scientifically designed to support lean muscle growth, not bulk, Equitop Myoplast Power Pearls is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
The product is endorsed by top British show jumper, Ellen Whitaker and veterinary surgeon and dressage rider, Christel Robbins BVSc MRCVS.
Craig Beck from Boehringer Ingelheim Vetmedica said: "Equitop Myoplast Power Pearls is already one of the most popular equine supplements sold in Germany and is used by top riders in all disciplines to help ensure their horses reach their full athletic potential. We are certain that with the support of riders such as Ellen Whitaker, Equitop Myoplast Power Pearls will prove just as popular in the UK."
Equitop Myoplast Power Pearls is available in a 1.5kg tub (RRP £65) and can be fed separately or mixed with feed. Horses weighing less than 500kg should be fed one scoop (25g) per day, while larger horses should receive two scoops (50g). Boehringer Ingelheim Vetmedica recommends that Equitop Myoplast Power Pearls is fed for at least a month as results are normally visible within 3-4 weeks.
Boehringer Ingelheim Vetmedica is committed to supporting veterinary practices and Equitop Myoplast Power Pearls will be distributed exclusively by veterinary wholesalers. An extensive advertising campaign in professional equine publications will help raise awareness of Equitop Myoplast Power Pearls and, for a limited period, horse owners and equine professionals can download a voucher from http://www.equitop-myoplast.co.uk/ offering a £15 rebate against their first purchase. Veterinary practices can redeem these vouchers by returning them to Boehringer Ingelheim Vetmedica via a freepost address.
For further information on Equitop Myoplast Power Pearls, please contact your local Boehringer Ingelheim Vetmedica representative, visit www.equitop-myoplast.co.uk or call 01344 746959.
Micro-nutrition specialist Agrimin has launched All-Trace Biotin Gold, the seventh bolus in the company's All-Trace range.
The new bolus is the result of extensive in-house research and development which aimed to formulate a cost-effective, micro-nutrition bolus suitable for dry cows and heifers at risk from lameness, which affects up to 20 per cent of the UK national herd. According to Agrimin, the relationship between Biotin and its benefits on ruminant hoof health is receiving increasing attention. The company says it is the first micro-nutrition specialist to directly address this livestock health issue by using a bolus.
The Biotin Gold bolus for dairy cows and heifers delivers the target level of 20 mg per head, per day of Biotin over 120 days. In addition, the bolus also delivers the full, daily requirement of copper, cobalt, selenium and iodine as well as levels of zinc, manganese and vitamins A, D3 and E.
Administration is simple and convenient during the drying off period as many livestock are already going through a crush to have their feet trimmed and undergo other healthcare routines such as intramammary treatments.
For dry cows, two boluses are given to each cow at the point of drying off. They lie in the rumen/reticulum and slowly dissolve from a constant surface area providing a continuous and regular supply of trace elements and vitamins to the animal. The boluses dissolve completely and leave no residue in the rumen.
Agrimin says heifers respond very well to Biotin supplementation and studies have shown that supplying Biotin in the later stages of pregnancy produces the most effective results. This late stage of pregnancy is also the critical period for the transfer of vital nutrients from mother to calf and so the trace element content of All-Trace Biotin Gold will benefit both animals. Two boluses are given to each heifer at around three months pre-calving.
All-Trace Biotin Gold is available in packs of 20 boluses, which will supplement 10 cows or heifers at a cost of around £9.50 per animal for two boluses. For more information about bolus technologies and micro-nutrition, please visit www.agrimin.com or call 01652 688046.
Two days left in which to enter Vetoquinol's competition to win up to £300 worth of CPD or a goody bag.
To enter, answer the 7 multi-choice questions here.
To mark its 20th anniversary, Woodley Equipment Company is holding a prize draw to win one of three bottles of Chateau Pitray 1989 Bordeaux red wine.
Woodley Equipment Company Ltd was established in 1989 by Mike Wickham, a biomedical scientist who specialises in haematology and blood transfusion.
Visit www.woodley20years.com to enter the draw. The winner will be drawn on Friday 30th October 2009.
Equistro® has produced a dust-free pelleted presentation of Secreta Pro, following requests from clients. Secreta Pro-Max® was launched to vets at BEVA Congress.
Secreta Pro is a respiratory supplement used to support the bronchial system and natural defences on a long term basis.
For more information on Secreta Pro-Max® and all Equistro products, please visit http://www.equistro.co.uk/, or contact your Vetoquinol representative.
Pet insurer esure has released the results of a survey of vets bills, carried out amongst 3000 pet owners.
Whilst the intent behind surveys like these may be laudable (i.e. to encourage more pet owners to insure their pets), they do the profession no favours, emphasising the high perceived costs of veterinary care rather than the good value that it generally represents.
This survey highlighted that:
esure's research showed that English Setters are the mostly costly breed of dog, forcing their owners to shell out £6,955 on vet bills, including injections, surgery and emergency treatments, in a lifetime.
Despite the potential for big bills, just a third (31 per cent) of pet owners have pet insurance and almost a quarter of those with cover admitted they were considering cancelling it to save money during the current credit crunch.
According to esure, many dog owners may be choosing to cancel or not even buy pet insurance because they are significantly underestimating the cost of treating common ailments and injuries. 29 per cent of pet owners surveyed think that the average vet bill for a dog with diabetes would be under £200, when it is actually £1146 including ongoing treatment*. To repair a dog's broken leg, 11 per cent of pet owners think that the average vet bill would be less than £100. It is actually more than five times that amount at £560*.
Mike Pickard, Head of esure pet insurance said: "Sickness, injury and long-term illness can affect any breed of dog, at any time, which is why it's crucial for pet owners to have insurance or ample savings to cover an unexpected vet bill of any size. With many pet owners underestimating the cost of treatment for common ailments, a hefty vet bill may stretch household finances to the limit - especially in the current credit crunch. Pet owners should plan ahead for all eventualities when it comes to their dog's health."
VET BILLS FOR THE TOP 10 MOST POORLY DOG BREEDS:
* Based on all claims received by pet insurance specialist, Thornside in 2008. http://www.bdml.co.uk/about-thornside.html
Woodley Equipment has launched the g-Pet species-specific glucose meter with a special introductory price of £9.50
Woodley says the g-Pet Glucometer makes testing quick easy and economical. Just insert a test strip, apply blood, and get results in 10 seconds.
The company highlights the following features of the new system:
Normal RRP is £49.50. Special introductory offer price is £9.50 for the next four weeks. Price includes meter, lancet, tips, 10 strips, manual, case and control solution.
For further information, or to organise a no-obligation in-practice demo, telephone 01204 669033 (option 1), or email: sales@woodleyequipment.com
Alternatively, visit www.woodleyequipment.com
Royal Canin has launched Breed Health Nutrition (BHN) foods for adult Dalmatians and French Bulldogs, bringing the company's portfolio of BHN foods up to a total of 19 dog breeds and four cat breeds.
Royal Canin vet marketing manager Ali Daff said: "Different breeds have different nutritional needs, varying from the sensitive digestion of the German Shepherd Dog to the ultra-long coat of the Persian cat. All our research and development is based on putting the animal first - what its real needs are in terms of nutrition to suit its characteristics and lifestyle.
"Veterinary practices are ideally placed to promote this idea to their clients, because they are talking to concerned and committed owners who want the best for their pets. In terms of nutrition, a tailormade diet offers the pet the best chance of maintaining a long and healthy life - and a good opportunity for practices to build client loyalty."
Royal Canin says the Dalmatian is the only canine breed which can be predisposed to excrete significant amounts of uric acid in the urine, a characteristic shared with man and the great apes. This uric acid, which is produced as a result of the metabolism of purines, can cause the formation of urinary calculi in some individuals. The simple reduction of the amount of purines in the diet means that the body produces less uric acid, reducing the risk of urate stones developing - hence the development of Dalmatian 22 Adult for dogs over 15 months. The diet is also specially developed to help support sensitive skin and intensify colour markings, as well as help maintain cardiac tone, support natural immunity, and support safe growth.
According to the company, the French Bulldog is renowned for its' sensitive digestion, so the use of very high quality, ultra-digestible proteins in French Bulldog 26 Adult help the diet deliver maximum nutritional value while helping reduce gastric fermentation (and odours as a result - a benefit many owners welcome!). Carefully balanced fibres and maximum palatability ensure the meal is eaten with gusto, while a specially developed kibble is easy for the dog to pick up and crunch, with associated dental benefits. High energy levels help maintain muscle mass, chondroitin sulphate and glucosamine provide joint support.
Ali Daff added: "These latest introductions are a very specific response to the needs of two special breeds, and will give veterinary practices another tool to help build and retain client loyalty."
Available from October 2009, Breed Health Nutrition foods are available from your Royal Canin Veterinary Business Manager, all good veterinary wholesalers, by calling 0800 717 800, or by visiting http://www.royalcanin.co.uk/.
The Disciplinary Committee of the Royal College of Veterinary Surgeons has suspended a veterinary surgeon for a period of three months for practising veterinary surgery while not registered with the College.
At a hearing which concluded on 9 September, Silke Birgitt Lindridge, of the Consett Veterinary Centre, Medomsley Road, Consett, County Durham, was found guilty of disgraceful conduct in a professional respect for practising when she ought to have known that her name had been removed from the RCVS Register for non-payment of fees.
The Committee heard that Mrs Lindridge, who qualified as a veterinary surgeon at the University of Berlin in 1997, had returned to Germany whilst on maternity leave in September 2006 but had continued to be the sole principal of two practices, the Consett Veterinary Centre, and the Winlaton Veterinary Centre in Tyne and Wear. She had continued to run the practices whilst in Germany, and had returned to the UK on several occasions during 2007, when she practised veterinary surgery on small animals and horses. She had not been registered with the College for the period between 5 June 2006 and 2 April 2008.
To practise veterinary surgery when unregistered is a criminal offence. However, after consultation with the Crown Prosecution Service, a decision was taken that it was not in the public interest to prosecute Mrs Lindridge and that the matter should be left with the RCVS Disciplinary Committee.
Mrs Lindridge claimed not to be aware that she was unregistered, stating that a fee notice and reminder, as well as a telephone call and correspondence from the College about her registration status, had not been brought to her attention by her practice administrators. The Committee accepted that she had not known, but decided that, as registration was a professional obligation, Mrs Lindridge should have known that her name had been removed from the Register, a charge that Mrs Lindridge accepted. The Committee felt that: "The failure of Mrs Lindridge to put in place proper systems for the administration of her practice, including the payment of her annual retention fee... was lamentable." The way in which the practice had paid its bills during her absence demonstrated an "utterly careless attitude to the administration of the practice".
Taking account of the fact that Mrs Lindridge had not knowingly practised while unregistered, and the positive support of her clients, the Committee decided that a three-month period of suspension from the Register was appropriate.
Beverley Cottrell, chairing the Committee, commented: "The Committee would like to make it clear that it is the personal responsibility of every practising veterinary surgeon to ensure that the annual retention fee is paid and that their names are on the Register. It is in the public interest that clients should be assured that the practitioner is a regulated person, who is capable of providing valid certificates."
She continued: "The record of Mrs Lindridge's practice during 2007 discloses that she was providing certificates for horses and small animals whilst she was unregistered. Those certificates are invalid. She was also prescribing prescription-only drugs when she was not entitled to do so. The Committee considers that a short period of suspension is proportionate to the nature and the extent of the charge, the public interest and the interests of Mrs Lindridge."
CEVA Animal Health has produced a leaflet to help horse owners understand the diagnosis and treatment of navicular disease.
Navicular disease can be difficult to diagnose and management of the condition can be a challenge for both vets and horse owners. The new leaflet helps owners get to grips with all aspects of the disease from the clinical signs to the procedures used to obtain a formal diagnosis. It then covers the various treatment options available including corrective farriery, analgesia, bisphosphonates and surgery. Diagrams and photographs help to ensure that the information is clear, concise and easy to follow.
The leaflet is available to equine vet practices as a useful information source for clients. Please order your free copies from your CEVA sales representative.
Norbrook Laboratories has launched Closamectin, a parasiticide which the company says will revolutionise cattle farming and parasite control in meat producing animals.
Closamectin Pour-on is a solution which can quite literally be poured onto the back of animals. It simultaneously treats fluke, worms and external parasites. The new product is the culmination of a six year research project costing £3.5 million and involving 80 scientists at the company's headquarters in Newry Co Down.
Norbrook says it will bring immense benefits for farmers whose cattle are often ravaged by parasitic attack. Fluke in particular can have devastating effects both on beef and dairy herds, seriously weakening, and in some cases killing the animals by destroying their livers. At the very least it collectively costs farmers around £17 million per annum by reducing the weight of beef cattle and the milk yields of dairy cows.
Fluke used to be confined to the western parts of Britain, together with Scotland and Ireland, but global warming has seen other parts of the UK experiencing the same mild and wet conditions on which the parasite thrives. Consequently it is on the rise.
Currently fluke is treated by injection or oral drench - both time-consuming and difficult processes for the farmers which can also be stressful for the animals. In contrast pour-on solutions can be applied swiftly and easily with no detrimental impact on cattle.
Norbrook has been awarded licenses for Closamectin Pour-on in both the UK and Ireland. This is a very significant market: the countries have a combined cattle population of 17 million. There are also plans to roll out the product in other countries.
Developing a pour-on to deal with these parasites has baffled scientists for 20 years. Alistair Couper, Norbrook's Chief Vet said: "This is the Holy Grail of farm animal veterinary medicine. It was a highly complex challenge for our research team. They had to develop a product which would treat different conditions simultaneously and have a molecular structure which could be absorbed straight through the skin. This is a ground breaking achievement and a brilliant piece of science"
Lord Ballyedmond, Chairman of Norbrook Laboratories said: "This is a very important milestone for Norbrook and for livestock and farmers worldwide. We have invested heavily in research and development and the results are there for all to see. We are delighted to have beaten other multinationals. We have now developed the world's most effective remedy for parasite control in cattle that our entering the food chain. I am pleased to state that our business has grown this year indigenously at 12% despite the recession, beating our competitors. This tremendous breakthrough is a great testimony to the brilliance of our scientists in Newry and also to our policy of investing in research. "